Russell K, Wiebe N, Saenz A, Ausejo Segura M, Johnson D, Hartling L, Klassen T P
Cochrane Database Syst Rev. 2004(1):CD001955. doi: 10.1002/14651858.CD001955.pub2.
Since the initial version of this systematic review in 1997, a number of randomised trials examining the benefit of glucocorticoids have been published, reflecting a continued interest in the use of glucocorticoids to treat patients with croup. The objective of this review was to provide evidence to guide clinicians in their treatment of patients with croup by determining the effectiveness of glucocorticoids and to identify areas of uncertainty for future research.
To determine the effect of glucocorticoids for children with croup.
We searched The Cochrane Central Register of Controlled Trials (CENTRAL) (issue 1, 2003), MEDLINE (January 1966 to April 2003) and Excerpta Medica/EMBASE (January 1974 to August 2003). We also contacted authors of identified croup trials published in the last ten years to inquire about additional published or unpublished trials.
Randomised controlled trials that examine children with croup and objectively measure the effectiveness of glucocorticoid treatment.
Based on review of the title and abstract (when available), two researchers identified studies for potential relevance. The complete text was retrieved and using a priori inclusion criteria, the studies were independently reviewed for relevance by two reviewers. Two observers independently assessed quality. Differences with respect to inclusion status and quality assessment were resolved by consensus. Data were extracted using a structured form by one reviewer and checked for accuracy by a second reviewer. Standard statistical analyses were performed.
Thirty-one studies were deemed relevant for inclusion (N = 3736). Glucocorticoid treatment was associated with an improvement in the Westley score at six hours with a weighted mean difference of -1.2 (95% confidence interval -1.6 to -0.8) and at 12 hours -1.9 (-2.4 to -1.3); at 24 hours this improvement was no longer significant (-1.3, -2.7 to 0.2). Fewer return visits and/or (re)admissions occurred in patients treated with glucocorticoids (relative risk 0.50; 0.36 to 0.70). Length of time spent in accident and emergency or hospital (weighted mean difference 12 hours, five to 19 hours) was significantly decreased for patients treated with glucocorticoids. Use of epinephrine decreased for children treated with a glucocorticoid (risk difference 10%; 1 to 20). No other decreases in additional treatments were found in the primary analysis. Publication bias does not impact results importantly. No between-trial significant differences were found between populations with mild and moderate croup. Oral dexamethasone may be superior to intramuscular dexamethasone.
REVIEWER'S CONCLUSIONS: Dexamethasone and budesonide are effective in relieving the symptoms of croup as early as six hours after treatment. Fewer return visits and/or (re)admissions are required and the length of time spent in hospital is decreased in inpatients. Dexamethasone is also effective in mild croup populations. Research is required to examine the most beneficial method for disseminating croup practice guidelines and to increase the uptake of evidence to improve outcomes.
自1997年本系统评价的初始版本发布以来,已经发表了一些关于糖皮质激素疗效的随机试验,这反映出人们持续关注使用糖皮质激素治疗哮吼患者。本评价的目的是通过确定糖皮质激素的有效性来为临床医生治疗哮吼患者提供证据,并确定未来研究的不确定性领域。
确定糖皮质激素对哮吼患儿的疗效。
我们检索了Cochrane对照试验中心注册库(CENTRAL)(2003年第1期)、MEDLINE(1966年1月至2003年4月)和医学文摘/EMBASE(1974年1月至2003年8月)。我们还联系了过去十年发表的已识别的哮吼试验的作者,询问其他已发表或未发表的试验。
检查哮吼患儿并客观测量糖皮质激素治疗效果的随机对照试验。
基于对标题和摘要(如有)的审查,两名研究人员确定了可能相关的研究。检索全文,并根据预先设定的纳入标准,由两名审阅者独立审查研究的相关性。两名观察者独立评估质量。关于纳入状态和质量评估的差异通过协商解决。由一名审阅者使用结构化表格提取数据,并由另一名审阅者检查准确性。进行标准统计分析。
31项研究被认为符合纳入标准(N = 3736)。糖皮质激素治疗与6小时时韦氏评分改善相关,加权平均差为-1.2(95%置信区间-1.6至-0.8),12小时时为-1.9(-2.4至-1.3);24小时时这种改善不再显著(-1.3,-2.7至0.2)。接受糖皮质激素治疗的患者复诊和/或再次入院的次数较少(相对风险0.50;0.36至0.70)。接受糖皮质激素治疗的患者在急诊或医院停留的时间(加权平均差12小时,5至19小时)显著缩短。接受糖皮质激素治疗的儿童肾上腺素的使用减少(风险差10%;1至20)。在初步分析中未发现其他额外治疗的减少。发表偏倚对结果影响不大。轻度和中度哮吼患者群体之间未发现试验间的显著差异。口服地塞米松可能优于肌肉注射地塞米松。
地塞米松和布地奈德在治疗后6小时内即可有效缓解哮吼症状。复诊和/或再次入院的次数减少,住院患者的住院时间缩短。地塞米松对轻度哮吼患者群体也有效。需要进行研究以检验传播哮吼实践指南的最有益方法,并提高证据的应用以改善治疗结果。